Skip to content
10-Q

Quarterly Report

Serina Therapeutics, Inc. SER

0001708599-26-000035

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 10, 2026 15M sh
Shares Diluted Q1 2026 · Mar 31, 2026 12.05M sh
Shares Diluted Q1 2026 · Mar 31, 2025 9.76M sh
Capex Q1 2026 · Mar 31, 2026 $25K
Capex Q1 2026 · Mar 31, 2025 $0
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$4.57M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$4.32M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $24.53M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $3.06M
Current Liabilities Q1 2026 · Mar 31, 2026 $6.34M
Current Liabilities Q1 2026 · Dec 31, 2025 $3.56M
Total Liabilities Q1 2026 · Mar 31, 2026 $9.67M
Total Liabilities Q1 2026 · Dec 31, 2025 $6.99M
Current Assets Q1 2026 · Mar 31, 2026 $26.47M
Current Assets Q1 2026 · Dec 31, 2025 $6.08M
Total Assets Q1 2026 · Mar 31, 2026 $27.3M
Total Assets Q1 2026 · Dec 31, 2025 $6.95M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.58
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.49
Eps Basic Q1 2026 · Mar 31, 2026 −$0.58
Eps Basic Q1 2026 · Mar 31, 2025 −$0.49
Sga Expense Q1 2026 · Mar 31, 2026 $3.08M
Sga Expense Q1 2026 · Mar 31, 2025 $2.91M
Rd Expense Q1 2026 · Mar 31, 2026 $3.2M
Rd Expense Q1 2026 · Mar 31, 2025 $2.95M
Net Income Q1 2026 · Mar 31, 2026 −$6.9M
Net Income Q1 2026 · Mar 31, 2025 −$4.81M